Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DMI019
- Development stage
- Phase 1
- Lead developer
- 江苏德迈药业
- Modality
- Small Molecules
- Administration
- Intranasal
01
Overview
DMI019 is an investigational nasal spray developed by Jiangsu Demai Pharmaceutical for the treatment of allergic rhinitis. It is a chemical drug currently in Phase I clinical development in China, where it is being evaluated for safety, tolerability, and pharmacokinetics in healthy volunteers. The drug is designed for intranasal administration to provide localized relief from symptoms such as nasal congestion, rhinorrhea, and sneezing by targeting the underlying inflammatory and allergic processes in the nasal mucosa. As a product of Jiangsu Demai's pipeline, which focuses on improved formulations and complex generics, DMI019 aims to offer a localized therapeutic effect with minimal systemic exposure.
Beyond the preview
Go deeper on DMI019.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DMI019.